FDA Approved Novartis AG’s Afinitor For Breast Cancer

Aug. 7 | The US Food and Drug Administration (FDA) has approved Afinitor® (everolimus) tablets for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ breast cancer) in combination with exemestane...

Drug Combos May Fight Advanced Breast Cancers

Dec. 15 | The researchers on breast cancer are reportedly encouraged by the results of two new studies that show combination therapies might improve survival for women with two different types of advanced tumors. One of the drugs, everolimus (Afinitor), boosted...

Afinitor Approved For Rare Type Of Pancreatic Cancer

May. 15 | The U.S. Food and Drug Administration (FDA) approved Afinitor (everolimus) to treat patients with progressive neuroendocrine tumors located in the pancreas (PNET) that cannot be removed by surgery or that have spread to other parts of the body (metastatic). This...

FDA Approves Afinitor

Nov. 30 | The US Food and Drug Administration (FDA) has approved Swiss pharmaceutical company Novartis’ drug Everolimus, which is marketed as Afinitor and is used for treating certain benign brain tumours which previously required surgery. Afinitor was found...